{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2004"],"condition":["Neoplasm Metastasis","Liver Metastases","Colorectal Cancer","Liver Neoplasms"],"disease":["Neoplasm Metastasis","Liver Metastases","Colorectal Cancer","Liver Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2016055"],"location":["Austria","Germany"],"study_start_month":["11"],"keyword":["Folic Acid","Irinotecan","Chemotherapy","Oxaliplatin","Liver resection","Resection","Levoleucovorin","Neoadjuvant","Leucovorin","Cetuximab","5-FU","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)","description":"General Objectives:\n* To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection\n* To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy","dates":{"creation":"2004-11-15"},"accession":"2016055","cross_references":{"ClinicalTrials___gov":["NCT00153998"]}}